News

Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?
In April, Danish drugmaker Novo Nordisk formed what was supposed to be a long-term collaboration to promote its weight-loss ...
Stock Movers: Novo Nordisk, IAG, Campari
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Fierce Biotech2h
Chutes & Ladders—Novo Nordisk nominates CEO successor
After the surprise departure of longtime CEO Lars Fruergaard Jørgensen in May, Danish pharma giant Novo Nordisk didn’t take ...
Novo Nordisk projects weaker sales as it battles copycat drugs
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
24/7 Wall St.2d
Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
Ozempic maker Novo Nordisk has its worst day since Black Monday
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Novo Nordisk: Catch That Falling Knife
Novo Nordisk stock drops 20%, but strong fundamentals, growth segments, and R&D pipeline make it an undervalued opportunity.
Novo Nordisk appoints new CEO Maziar Doustdar
July 29 (UPI) -- Novo Nordisk announced Tuesday that Mike Doustdar has been appointed as the company's new CEO. Doustdar ...
Free Malaysia Today on MSN2h
Novo Nordisk’s shares extend losses, erasing nearly all gains since Wegovy launch
Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions ...
Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...